Company: DAWN
Filing Date: 2025-11-13
Form Type: SC TO-C
Source: 0001104659-25-110815
Chunk: 9

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-11-13
Form: SC TO-C
Chunk 9
---
 made available
an investor presentation containing details of the proposed transaction and its potential impact on Parent. A copy of the investor presentation
is attached hereto as Exhibit 99.2.

On November 13, 2025, Parent made available
a corporate presentation containing an overview of the Parent’s pipeline, financial results and opportunities. A copy of the corporate
presentation is attached hereto as Exhibit 99.3.

This information and Exhibits 99.1, 99.2 and 99.3 are being furnished pursuant to Item 7.01 of this report and shall not be deemed to be “filed”
for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and will not be incorporated
by reference into any registration statement filed by Parent under the Securities Act of 1933, as amended, unless specifically identified
as being incorporated therein by reference. This report will not be deemed an admission as to the materiality of any information in this
Item 7.01 or Exhibits 99.1, 99.2 and 99.3.

Cautionary Note Regarding Forward-Looking Statements

This report contains forward-looking statements.
Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”,
“intends”, “estimates”, “plans”, “will”, “goal” and similar expressions. These
forward-looking statements include, without limitation, statements related to the proposed Offer, Merger and related transactions contemplated
by the Merger Agreement and the CVR Agreement and the expected timing thereof; the expected benefits from the acquisition of Target, and
other statements that are not historical facts. These forward-looking statements are based on Parent’s current expectations and
inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Parent’s
ability to complete the transactions on the proposed terms and schedule, or at all; whether the various conditions to the consummation
of the transactions under the Merger Agreement will be satisfied or waived; whether stockholders of Target tender sufficient Target Shares
in the Offer; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement;
the outcome of legal proceedings that may be instituted against Parent, Target and/or others relating to the transactions and the risk